Zonnebodo Pharmaceutical

Zonnebodo Pharmaceutical is a clinical-stage biopharmaceutical company based in China, primarily focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and obesity. The company's lead candidate, benaglutide, is a GLP-1 receptor agonist that has undergone extensive clinical testing to demonstrate efficacy in glycemic control and weight management. Zonnebodo aims to address the growing burden of metabolic disorders through the development of both injectable and potentially oral formulations of incretin-based therapies. The company maintains a robust clinical pipeline with programs ranging from early-stage research to late-stage Phase 3 confirmatory trials.